
Exploring the Wide World of GLP-1s | AMCP Annual 2025
First, it was Type 2 diabetes. Then it was weight loss, and next, cardiovascular disease. Still more possible uses of the glucagon-like peptide 1 (GLP-1) drugs were discussed this morning at a keynote session this morning on the last day of the annual …